Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: what are we missing?

Ann Oncol. 2023 Sep;34(9):729-731. doi: 10.1016/j.annonc.2023.06.008. Epub 2023 Jul 3.

Authors

U De Giorgi¹, E F Giunta², E Verzoni³, G Procopio³

Affiliations

¹ Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola. Electronic address: ugo.degiorgi@irst.emr.it.
² Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola.
³ Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

PMID: 37406813
DOI: 10.1016/j.annonc.2023.06.008

No abstract available

Publication types

Editorial
Comment

MeSH terms

Androgen Receptor Antagonists
Androgens / metabolism
Antineoplastic Agents* / therapeutic use
Humans
Male
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / pathology
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / pathology
Receptors, Androgen

Substances

Androgen Receptor Antagonists
Androgens
Antineoplastic Agents
Poly(ADP-ribose) Polymerase Inhibitors
Receptors, Androgen